<DOC>
	<DOCNO>NCT02865330</DOCNO>
	<brief_summary>Description : Multicentre observational study , randomize . Ambispective character ( retro prospective ) . Opened member Asociación Española de Urología ( AEU ) , public private medicine . Justification : Active surveillance strategy propose control overtreatment derive opportunist screen prostate cancer ( PCa ) . Its development country erratic different every Center . This database try include patient include active surveillance Spain minimal inclusion criterion . Multicentre registry follow active surveillance Spain . Hypothesis : Mortality cancer specific PCa includible active surveillance 15 year low 5 % .</brief_summary>
	<brief_title>Spanish Urological Association Registry Patients Active Surveillance</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . PSA ≤ 10 ng / mL ; prostate volume &gt; 60 cc transrectal , ultrasound includable PSA &gt; 10 ng / ml PSAD &lt; 0.20 2 . Local Stadium DRE ; cT1c cT2a 3 . Diagnosis transrectal ultrasound guide biopsy minimum 10 cylinder 4 . Adenocarcinoma Prostate Gleason ≤ 6 ( 3 + 3 ) local central pathology review 5 . Maximum number cylinder = 2 none 5mm tumor 50 % assignment 6 . &lt; 80 year great expectancy 10 year life ( Charlson score ) 7 . Patients able understand active surveillance sign Informed Consent 1 . Patient able accept repeat biopsy 2 . Patient want sign Informed Consent 3 . Hospital possibility biopsy confirmation 6 month guarantee term inclusion criterion 4 . Patients history ASAP ( atypical small acinar proliferation atypical microglands ) 5 . Patients treatment inhibitor 5alphareductase dutasteride ( Avidart® ) finasteride ( Proscar® ) previous six month 6 . Patients undergone 6 month prior treatment symptomatic benign prostate hyperplasia , invasive urological procedure . It associate increase PSA prior phlebotomy . These therapy include , limited , prostate biopsy , thermotherapy , microwave therapy , laser , urethral resection prostate , urethral catheterization lower genitourinary tract endoscopy .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Intermediate Risk Prostate Cancer</keyword>
	<keyword>Low Risk Prostate Cancer</keyword>
	<keyword>Active Surveillance</keyword>
</DOC>